Thanks for everyone that participated! Special thanks to Larry Meyer, Head of Clinical Genomics at the VA, who provided some very useful information - Larry - we want you to be part of our group!
Here are the references, plus some on multiple deployments increasing the risk of PTS:
1. Bush, N.E. et al. Suicides and Suicide Attempts in the U.S.Military, 2008–2010. Suicide and Life-Threatening Behavior. 2013; 43(3): 262-273.
2. Trofimovich, L. et al. Suicide Risk by Military Occupation in the DoD Active Component Population. Suicide and Life-Threatening Behavior. 2013; 43(3): 274-278.
PTS / PTSD:
1. Santiago, P.N. et al. A Systematic Review of PTSD Prevalence and Trajectories in DSM-5 Defined Trauma Exposed Populations: Intentional and Non-Intentional Traumatic Events. PLoS ONE. 2013; 8(4): e59236. doi:10.1371/journal.pone.0059236.
2. Solomon Z, Mikulincer M. Trajectories of PTSD: a 20-year longitudinal study. American Journal of Psychiatry . 2006. 163: 659–666.
3. Kok, B.A.et al. Posttraumatic stress disorder associated with combat service in Iraq or Afghanistan: Reconciling prevlance differences between studies. J. Mental & Nervous Dis. 2012: 200(5): 444-450.
PTS / PTSD and association with number of deployments:
1. Vasterline, J.J. et al. PTSD Symptom Increases in Iraq-Deployed Soldiers: Comparison With Nondeployed Soldiers and Associations With Baseline Symptoms, Deployment Experiences, and Postdeployment Stress. J. Traumatic Stress. 2010; 23(1): 41-51.
2. Meger, M.A. et al. Association between the number of deployments to Iraq and mental health screening outcomes in U.S. Army soldiers. J. Clinical Psychiatry. 2009; 70(9): 1266-1272.
3. Kline, A. et al. Effects of repeated deployments to Iraq and Afghanistan on the health of New Jersey National Guard Trropps: IMplications for medical readiness. American Journal of Public Health: February 2010; 100(2): 276-283.
MAJOR DEPRESSIVE DISORDER and TREATMENT-RESISTANT DEPRESSION:
1. Treatment Resistant Depression: A Roadmap for Effective Care. (Eds. Greden, JF, Riba, MB and McInnis, MG). American Psychiatric Publishing. 2011. Washington, DC. ISBN: 978-1-58562-409-6.
2.Carney, R.M. & Freedland, K.F. Treatment-resistant depression and mortality after acute coronary syndrome. Am. J. Psychiatry. 2009: 166(4): 410-417.
3. Freedland, K.F. & Carney, R.M. Depression as a risk factor for adverse outcomes in coronary heart disease. BMC Medicine. 2013: 11:131-140.
THE ROLE OF EPIGENOMICS IN THE ETIOLOGY OF PTS / PTSD:
1. van Wingen GA et al. Perceived threat predicts the neural sequeale of combat stress. Mol. Psychiatry. 2011. 16(6): 664–671.
2. van Zuiden M et al. Glucocorticoid Receptor Pathway Components Predict Posttraumatic Stress Disorder Symptom Development: A Prospective Study. Biol Psychiatry. 2011.
3. Baker DG et al. Higher levels of basal serial CSF cortisol in combat veterans with posttraumatic stress disorder. Am J Psychiatry. 2005. 162:992–994.
4. Crews D et al. Epigenetic transgenerational inheritance of altered stress responses. Proc Natl Acad Sci. 2012. 109:9143–9148.
5. Skelton, K. et al. PTSD and gene variants: New pathways and new thinking. Neuropharmacology. 2012: 62(2):628-637.
6. Mehta D & Binder EB. Gene × environment vulnerability factors for PTSD: the HPA-axis. Neuropharmcology. 2012: 62(2): 654-662.
7. Yehuda, R. et al. The role of genes in defining a molecular biology of PTSD. Dis. Markers. 2011; 30: 67-76.
CLINICAL DECISION SUPPORT, PHARMACOGENOMICS AND THE EHR:
1. Kawamoto K et al. A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Medical Informatics and Decision Making. 2009. 9:17 doi:10.1186/1472-6947-9-17.
2. Kawamoto, K., Hongsermeier, T., Wright, A. et al. Key principles for a national clinical decision support knowledge sharing framework: synthesis of insights from leading subject matter experts. 2013. J Am Med Inform Assoc 20:199-207.
3. Welch, B.M & Kawamoto, K. Clinical decision support for genetically guided personalized medicine: a systematic review. J Am Med Inform Assoc (2012). doi:10.1136/amiajnl-2012-000892.
4. Middleton, B. et al. Enhancing patient safety and quality of care by improving the usability of electronic health record systems: recommendations from AMIA. J Am Med Inform Assoc 2013;0:1–7. doi:10.1136/amiajnl-2012-001458 1.
PRE-EMPTIVE GENOTYPING AND THE EHR:
1. Schildcrout, J.S. et al. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin. Pharm Therap. 2012; 92(2): 235-242.
2. Pulley, J.M., Denny, J.C., Peterson, J.F. et al. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 2012;92(1): 87–95.
3. Roden, D.D., Xu, H., Denny, J.C. et al. Electronic medical records as a tool in clinical pharmacology: Opportunities and challenges. Clin. Pharmacol. Ther. 2012; 91(6): 1083-1086.
INTEGRATION OF ‘OMIC’ DATA AND THE EHR:
1. Masys DR, Jarvik GP, Abernethy NF et al. Technical desiderata for the integration of genomic data into electronic health records. J. Biomed. Inform. 2012; 45(3), 419–422.
2. Gottesman, O. et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genetics Medicine. 2013; 2013/06/06/online.
3. Chute, C.G. & Kohane, I.S. Genomic medicine, health information technology, and patient care. JAMA. 2013: 309(14): 1467-1468.